Canada changes tack, recommends use of Astra vaccine in people over 65

The National Advisory Committee on Immunization said it was basing its new guidelines on three recent real-world studies that examined the effectiveness of the vaccine

AstraZeneca
The committee had said on March 1 that AstraZeneca doses should only be given to those aged from 18 to 64 because clinical trials had featured very few people 65 or older | Photo: Reuters
Reuters
2 min read Last Updated : Mar 16 2021 | 8:15 PM IST
A panel of Canadian health experts on Tuesday said AstraZeneca's COVID-19 vaccine could be used in people aged 65 years and older after initially recommending against the idea.
 
The National Advisory Committee on Immunization said it was basing its new guidelines on three recent real-world studies that examined the effectiveness of the vaccine. (https://bit.ly/3thLc1Q) The committee had said on March 1 that AstraZeneca doses should only be given to those aged from 18 to 64 because clinical trials had featured very few people 65 or older.
 
"There is now real-world evidence from the United Kingdom (which) who has been administering the AstraZeneca vaccine to people 65 years of age and older. This evidence demonstrates that the vaccine is safe and effective in older adults," the committee said in a statement.
 
Germany, France and Italy said on Monday they would suspend AstraZeneca COVID-19 shots after several countries reported possible serious side-effects. In response, Prime Minister Justin Trudeau said Canadian health experts felt it was safe.
 
Canada has recorded a total of 22,495 deaths from the coronavirus and 913,047 cases. Health officials in Ontario, the most populous of the 10 provinces, say they are seeing clear signs of a third wave.
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :AstraZenecaCoronavirus VaccineCanada

Next Story